Telomir Pharmaceuticals (NASDAQ:TELO) Stock Price Up 3.3% – What’s Next?

Telomir Pharmaceuticals, Inc. (NASDAQ:TELO)’s share price rose 3.3% on Thursday . The company traded as high as $1.28 and last traded at $1.27. Approximately 34,484 shares changed hands during mid-day trading, a decline of 60% from the average daily volume of 86,109 shares. The stock had previously closed at $1.23.

Analysts Set New Price Targets

TELO has been the topic of a number of research analyst reports. Wall Street Zen upgraded Telomir Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Saturday, February 21st. Weiss Ratings reiterated a “sell (e+)” rating on shares of Telomir Pharmaceuticals in a report on Tuesday, April 21st. Finally, Zacks Research raised Telomir Pharmaceuticals to a “hold” rating in a research report on Wednesday, March 18th. One research analyst has rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the company has a consensus rating of “Hold”.

Telomir Pharmaceuticals Price Performance

The firm has a 50-day simple moving average of $1.31 and a 200 day simple moving average of $1.31. The company has a market capitalization of $87.35 million, a PE ratio of -4.38 and a beta of -0.24.

Telomir Pharmaceuticals (NASDAQ:TELO) last released its quarterly earnings data on Thursday, May 14th. The company reported ($0.03) EPS for the quarter, beating the consensus estimate of ($0.07) by $0.04.

Hedge Funds Weigh In On Telomir Pharmaceuticals

Institutional investors have recently added to or reduced their stakes in the company. OneDigital Investment Advisors LLC lifted its holdings in Telomir Pharmaceuticals by 64.3% in the 3rd quarter. OneDigital Investment Advisors LLC now owns 23,000 shares of the company’s stock worth $32,000 after buying an additional 9,000 shares in the last quarter. Qube Research & Technologies Ltd acquired a new position in shares of Telomir Pharmaceuticals in the second quarter worth about $33,000. World Investment Advisors acquired a new position in shares of Telomir Pharmaceuticals in the fourth quarter worth about $47,000. XTX Topco Ltd acquired a new position in shares of Telomir Pharmaceuticals in the fourth quarter worth about $53,000. Finally, Bank of America Corp DE lifted its stake in shares of Telomir Pharmaceuticals by 283.9% in the fourth quarter. Bank of America Corp DE now owns 14,713 shares of the company’s stock worth $61,000 after acquiring an additional 10,880 shares in the last quarter.

About Telomir Pharmaceuticals

Telomir Pharmaceuticals, Inc (NASDAQ: TELO) is a clinical-stage biopharmaceutical company focused on the discovery and development of novel small-molecule therapies for cardiometabolic and fibrotic diseases. Leveraging a proprietary target discovery platform, the company aims to identify and modulate key biological pathways implicated in tissue fibrosis, inflammation and metabolic dysregulation. Its research strategy centers on oral agents intended to address high-unmet-need conditions such as nonalcoholic steatohepatitis (NASH) and systemic fibrotic disorders, where existing treatment options are limited.

The company’s lead development candidate is an oral inhibitor currently in early-phase clinical trials that targets growth factors involved in fibrotic tissue remodeling.